Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine a blood concentrations

Journal of Pharmacological Sciences

Volumn 124, Issue 2, 2014, Pages 180-191

  Kawauchi, Shoji ^a   Nakamura, Tsutomu ^c   Miki, Ikuya ^a,b   Inoue, Jun ^a,b   Hamaguchi, Tsuneo ^a   Tanahashi, Toshihito ^a,b   Mizuno, Shigeto ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

Cyclosporine A; Cytochrome P450 3A; Dextran sulfate sodium; Experimental colitis model; P glycoprotein

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOSPORIN A; CYTOCHROME P450 3A; DEXTRAN; INDUCIBLE NITRIC OXIDE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN; MYELOPEROXIDASE; PREGNANE X RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DEXTRAN SULFATE SODIUM INDUCED COLITIS; DISEASE ACTIVITY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; INFLAMMATION; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMALL INTESTINE; TRANSCRIPTION INITIATION;

ANIMALS; BIOLOGICAL AVAILABILITY; COLITIS, ULCERATIVE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DEXTRAN SULFATE; DOWN-REGULATION; HUMANS; INTESTINE, SMALL; LIVER; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; P-GLYCOPROTEIN; RECEPTORS, STEROID;

EID: 84895543072     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13141FP     Document Type: Article

References (46)

1. Zhou S, Chan SY, Goh BC, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44: 279-304.
2. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34: 880-886.
3. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, et al. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol. 2006;72: 1042-1050.
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9: 215-236.
5. Smit JW, Schinkel AH, Weert B, Meijer DK. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol. 1998;124: 416-424.
6. Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol. 2004;18: 621-626.
7. Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, et al. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharm. 2006;309: 81-86.
8. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009;69: 8996-9002.
9. Masubuchi Y, Horie T. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab Dispos. 2004;32: 437-441.
10. Chaluvadi MR, Nyagode BA, Kinloch RD, Morgan ET. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem Pharmacol. 2009;77: 464-471.
11. Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrini G. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clin Pharmacol Ther. 1988;44: 642-649.
12. Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res. 1998;15: 706-711.
13. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther. 2006;80: 235-245.
14. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
15. Kimmelstein P, Large HL, Vemner HD. Liver damage inulcerative colitis. Am J Pathol. 1952;28: 259-279.
16. Broomé U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut. 1994;35: 84-89.
17. Memon MI, Memon B, Memon MA. Hepatobiliary manifestations of inflammatory bowel disease. HPB Surg. 2000;11: 363-371.
18. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69: 238-249.
19. Yoshihara K, Yajima T, Kubo C, Yoshikai Y. Role of interleukin 15 in colitis induced by dextran sulfate sodium in mice. Gut. 2006;55: 334-341.
20. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87: 1344-1350.
21. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci. 2007;52: 2095-2103.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25: 402-408.
23. Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol. 2005;69: 1745-1754.
24. Beresini MH, Davalian D, Alexander S, Toton-Quinn R, Barnett B, Cerelli MJ, et al. Evaluation of EMIT Cyclosporine Assay for use with whole blood. Clin Chem. 1993;39: 2235-2241.
25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98: 694-702.
26. Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999;44: 1458-1475.
27. Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, et al. NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2005;50: 2366-2378.
28. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15: 341-352.
29. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Büchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 2000;62: 240-248.
30. Brooke BN, Slaney G. Portal bacteraemia in ulcerative colitis. Lancet. 1958;1: 1206-1207.
31. Eade MN, Brook BN. Portal bacteraemia in cases of ulcerative colitis submitted to colectomy. Lancet. 1969;1: 1008-1009.
32. Masubuchi Y, Enoki K, Horie T. Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos. 2008;36: 597-603.
33. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med. 1989;111: 561-566.
34. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83: 633-671.
35. Faber KN, Müller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003;55: 107-124.
36. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 2006;290:G923-G932.
37. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol. 2001;1: 189-199.
38. Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002;303: 273-281.
39. Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005;289:G831-G841.
40. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35: 1032-1041.
41. Li H, Wang H. Activation of xenobiotic receptors: driving into the nucleus. Expert Opin Drug Metab Toxicol. 2010;6: 409-426.
42. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32: 20-27.
43. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006;281: 17882-17889.
44. Lee CM, Kim BY, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem. 2008;283: 889-898.
45. Nawa A, Fujita-Hamabe W, Tokuyama S. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model. Drug Metab Pharmacokinet. 2012;27: 548-552.
46. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62: 248-260.